Hung Jeffrey Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hung Jeffrey Kim has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Carmen C. Brewer
Audiology Unit, Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, USA
3 shared publicationsKelly A. King
Audiology Unit, Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, USA
3 shared publicationsChristopher K. Zalewski
Audiology Unit, Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, USA
2 shared publications- Abdul Rashid
Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC
1 shared publication - Alexander X. Tai
Department of Neurosurgery and Brain Repair, University of South Florida, 2 Tampa General Circle, Tampa, FL 33606, USA
1 shared publication - Alexis Strohl
Department of Otolaryngology Head and Neck Surgery, University of Rochester Rochester, NY, USA
1 shared publication
Latest Publications
- 11 November 2026
- Published by Wolters Kluwer Health in Otology & Neurotology
Reconsidering the Management of Middle Ear Myoclonus: A Case Series Presentation and Systematic Review of Surgical Outcomes Following Lysis of the Tensor Tympani and Stapedial Tendons
Objective: To present a two patient case series and systematically review clinical characteristics and outcomes of middle ear myoclonus (MEM) and to evaluate whether lysis of the tensor tympani (TT) and/or stapedial tendon (ST) should be considered as an alternative to medical therapy to treat this condition. Databases reviewed: MEDLINE, Embase, CENTRAL, and Web of Science. Methods: Two institutional cases (3 ears) operated on from March through August 2025 were retrospectively analyzed. We then systematically identified English-language studies published before August 2025 and screened them using predefined criteria. Two independent reviewers (C.Z., D.S.) extracted data on demographics, symptom duration, prior medical therapy, surgical procedure (TT and/or ST lysis), technique, laterality, and outcomes. We then used descriptive statistics. Results: Both patients (3 ears) in the case series achieved complete symptom resolution. Of 756 screened articles, 17 met criteria for full-text review, contributing 70 patients. Combined with the case series, the total cohort comprised 72 patients, of whom 60 (83.3%) had previously tried anticonvulsants, antispasmodics, tranquilizers, sedatives, and/or muscle relaxants, while 12 (16.7%) underwent surgery as initial treatment. Complete symptom resolution occurred in 67 patients (93.1%), partial improvement in 4 (5.5%), and symptom recurrence in 1 (1.4%). Conclusion: TT and/or ST lysis is a safe and effective treatment for MEM with high rates of symptom resolution. Surgical intervention should be considered early in appropriate patients, and patients should be appropriately counseled regarding the high likelihood of complete symptom resolution with surgical intervention.
- 11 November 2026
- Published by Wolters Kluwer Health in Otology & Neurotology
Reconsidering the Management of Middle Ear Myoclonus: A Case Series Presentation and Systematic Review of Surgical Outcomes Following Lysis of the Tensor Tympani and Stapedial Tendons
Objective: To present a two patient case series and systematically review clinical characteristics and outcomes of middle ear myoclonus (MEM) and to evaluate whether lysis of the tensor tympani (TT) and/or stapedial tendon (ST) should be considered as an alternative to medical therapy to treat this condition. Databases reviewed: MEDLINE, Embase, CENTRAL, and Web of Science. Methods: Two institutional cases (3 ears) operated on from March through August 2025 were retrospectively analyzed. We then systematically identified English-language studies published before August 2025 and screened them using predefined criteria. Two independent reviewers (C.Z., D.S.) extracted data on demographics, symptom duration, prior medical therapy, surgical procedure (TT and/or ST lysis), technique, laterality, and outcomes. We then used descriptive statistics. Results: Both patients (3 ears) in the case series achieved complete symptom resolution. Of 756 screened articles, 17 met criteria for full-text review, contributing 70 patients. Combined with the case series, the total cohort comprised 72 patients, of whom 60 (83.3%) had previously tried anticonvulsants, antispasmodics, tranquilizers, sedatives, and/or muscle relaxants, while 12 (16.7%) underwent surgery as initial treatment. Complete symptom resolution occurred in 67 patients (93.1%), partial improvement in 4 (5.5%), and symptom recurrence in 1 (1.4%). Conclusion: TT and/or ST lysis is a safe and effective treatment for MEM with high rates of symptom resolution. Surgical intervention should be considered early in appropriate patients, and patients should be appropriately counseled regarding the high likelihood of complete symptom resolution with surgical intervention.
- Open Access
- 19 July 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (12) , 4490-4498
Contemporary Clinical Management of Otosyphilis for Practicing Otolaryngologists—A Scoping Review
Objective: The COVID‐19 pandemic marked the resurgence of an old disease, syphilis. The CDC reported increased syphilis cases in the United States from 2016 to 2022, necessitating early recognition of syphilis to properly diagnose complications. We revisit otosyphilis management with the intent of developing an updated diagnostic testing algorithm and treatment plan for otolaryngologists to prevent worsening hearing loss. Data Sources: MEDLINE, PubMed, Embase, Web of Science, and Cochrane databases. Methods: A scoping review of diagnostic and treatment methods for otosyphilis was completed and reported in compliance with the guidelines outlined in the PRISMA‐ScR extension for scoping reviews statement. A retrospective case series was also conducted by reviewing patient charts from a tertiary care hospital network. Patients with otosyphilis or neurosyphilis with otic symptoms, as diagnosed by an otolaryngology or infectious disease specialist, were included. Results: In 57 studies (222 patients), the mean reported symptom duration was 6.6 ± 5.0 weeks ( n = 30) with nine outliers presenting after 6 months (65%) had hearing loss, 95 (43%) tinnitus, and 53 (24%) vertigo. Most (97%) received penicillin. Of 84 with outcomes, 48 (57%) improved. In 18 additional patients from the tertiary hospital system cohort (17 males, 1 female; 25–87 years, 9 HIV‐positive), penicillin or doxycycline was used. Six patients fully recovered, four required further therapy, two partially recovered, and one did not improve. Conclusion: Otosyphilis has an insidious presentation and can mimic other audiovestibular demanding early testing. Complex serologic interpretation may require referral to infectious disease specialists. Clear diagnostic protocols ensure timely treatment and improved outcomes.
- 19 July 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (12) , 4490-4498
Open AccessContemporary Clinical Management of Otosyphilis for Practicing Otolaryngologists—A Scoping Review
Objective: The COVID‐19 pandemic marked the resurgence of an old disease, syphilis. The CDC reported increased syphilis cases in the United States from 2016 to 2022, necessitating early recognition of syphilis to properly diagnose complications. We revisit otosyphilis management with the intent of developing an updated diagnostic testing algorithm and treatment plan for otolaryngologists to prevent worsening hearing loss. Data Sources: MEDLINE, PubMed, Embase, Web of Science, and Cochrane databases. Methods: A scoping review of diagnostic and treatment methods for otosyphilis was completed and reported in compliance with the guidelines outlined in the PRISMA‐ScR extension for scoping reviews statement. A retrospective case series was also conducted by reviewing patient charts from a tertiary care hospital network. Patients with otosyphilis or neurosyphilis with otic symptoms, as diagnosed by an otolaryngology or infectious disease specialist, were included. Results: In 57 studies (222 patients), the mean reported symptom duration was 6.6 ± 5.0 weeks ( n = 30) with nine outliers presenting after 6 months (65%) had hearing loss, 95 (43%) tinnitus, and 53 (24%) vertigo. Most (97%) received penicillin. Of 84 with outcomes, 48 (57%) improved. In 18 additional patients from the tertiary hospital system cohort (17 males, 1 female; 25–87 years, 9 HIV‐positive), penicillin or doxycycline was used. Six patients fully recovered, four required further therapy, two partially recovered, and one did not improve. Conclusion: Otosyphilis has an insidious presentation and can mimic other audiovestibular demanding early testing. Complex serologic interpretation may require referral to infectious disease specialists. Clear diagnostic protocols ensure timely treatment and improved outcomes.
- Open Access
- 19 July 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-10
Characterization of hearing-impairment in Generalized Arterial Calcification of Infancy (GACI)
Background and importance: Hearing loss (HL) has been sporadically described, but not well characterized, in Generalized Arterial Calcification of Infancy (GACI), a rare disease in which pathological calcification typically presents in infancy. Objectives: This study aims to describe the clinical audiologic and otologic features and potential etiology of hearing impairment in GACI and gain pathophysiological insight from a murine model of GACI. Design: Cross-sectional cohort study of individuals with GACI. Murine ossicle micromorphology of the ENPP1asj/asj mutant compared to wild-type. Setting: Clinical research hospital; basic science laboratory. Participants: Nineteen individuals with GACI who met clinical, biochemical, and genetic criteria for diagnosis. Main outcomes and measures: Clinical, biochemical, and radiologic features associated with hearing status. Results: Pure-tone thresholds could be established in 15 (n = 30 ears) of the 19 patients who underwent audiological assessments. The prevalence of HL was 50% (15/30) of ears, with conductive HL in 80% and sensorineural HL in 20%. In terms of patients with HL (n = 8), seven patients had bilateral HL and one patient had unilateral HL. Degree of HL was mild to moderate for 87% of the 15 ears with hearing loss. Of those patients with sufficient pure-tone and middle ear function data, 80% (8/10) had audiometric configurations suggestive of ossicular chain dysfunction (OCD). Recurrent episodes of otitis media (ROM) requiring pressure-equalizing tube placement were common. In patients who underwent cranial CT, 54.5% (6/11) had auricular calcification. Quantitative backscattered electron imaging (qBEI) of murine ossicles supports an OCD component of auditory dysfunction in GACI, suggesting loss of ossicular osteocytes without initiation of bone remodeling. Conclusions and relevance: Hearing loss is common in GACI; it is most often conductive, and mild to moderate in severity. The etiology of HL is likely multifactorial, involving dysfunction of the ossicular chain and/or recurrent otitis media. Clinically, this study highlights the importance of early audiologic and otologic evaluation in persons with GACI. Novel findings of high rates of OCD and ROM may inform management, and in cases of unclear HL etiology, dedicated temporal bone imaging should be considered.
- 19 July 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-10
Open AccessCharacterization of hearing-impairment in Generalized Arterial Calcification of Infancy (GACI)
Background and importance: Hearing loss (HL) has been sporadically described, but not well characterized, in Generalized Arterial Calcification of Infancy (GACI), a rare disease in which pathological calcification typically presents in infancy. Objectives: This study aims to describe the clinical audiologic and otologic features and potential etiology of hearing impairment in GACI and gain pathophysiological insight from a murine model of GACI. Design: Cross-sectional cohort study of individuals with GACI. Murine ossicle micromorphology of the ENPP1asj/asj mutant compared to wild-type. Setting: Clinical research hospital; basic science laboratory. Participants: Nineteen individuals with GACI who met clinical, biochemical, and genetic criteria for diagnosis. Main outcomes and measures: Clinical, biochemical, and radiologic features associated with hearing status. Results: Pure-tone thresholds could be established in 15 (n = 30 ears) of the 19 patients who underwent audiological assessments. The prevalence of HL was 50% (15/30) of ears, with conductive HL in 80% and sensorineural HL in 20%. In terms of patients with HL (n = 8), seven patients had bilateral HL and one patient had unilateral HL. Degree of HL was mild to moderate for 87% of the 15 ears with hearing loss. Of those patients with sufficient pure-tone and middle ear function data, 80% (8/10) had audiometric configurations suggestive of ossicular chain dysfunction (OCD). Recurrent episodes of otitis media (ROM) requiring pressure-equalizing tube placement were common. In patients who underwent cranial CT, 54.5% (6/11) had auricular calcification. Quantitative backscattered electron imaging (qBEI) of murine ossicles supports an OCD component of auditory dysfunction in GACI, suggesting loss of ossicular osteocytes without initiation of bone remodeling. Conclusions and relevance: Hearing loss is common in GACI; it is most often conductive, and mild to moderate in severity. The etiology of HL is likely multifactorial, involving dysfunction of the ossicular chain and/or recurrent otitis media. Clinically, this study highlights the importance of early audiologic and otologic evaluation in persons with GACI. Novel findings of high rates of OCD and ROM may inform management, and in cases of unclear HL etiology, dedicated temporal bone imaging should be considered.
- 28 July 2021
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 42 (10) , e1614-e1617
Reconstruction of the Anterior External Auditory Canal With Mastoid Cortex Autologous Bone Graft
Objective: To describe the surgical management of temporomandibular joint (TMJ) herniation with external auditory canal (EAC) reconstruction using autologous bone grafting from the mastoid cortex. Study Design: Retrospective case series. Setting: A tertiary university medical center. Patients: Three patients who presented to our Otolaryngology clinic with evidence of TMJ herniation through an anterior EAC defect, both on otoscopy and computed tomography (CT) imaging. Interventions: Reconstruction of the anterior EAC with mastoid cortex bone grafting using an endaural approach. Main Outcome Measures: Successful reconstruction of anterior EAC bony defect without recurrence of herniation. Results: All three patients presented with otalgia, hearing loss, and either tinnitus or a clicking sensation with jaw movement. Etiologies for TMJ herniation included osteoradionecrosis following external beam radiation therapy for head and neck carcinoma and iatrogenic injury following multiple tympanoplasties and canalplasties. A mastoid cortex bone graft was placed and secured anterior to the bony EAC defect through an endaural approach. Two patients wore a dental retainer postoperatively to keep the condyle in an open position. After reconstruction, patients reported an improvement in their presenting symptoms. There was no recurrence of TMJ herniation in all cases after 1, 4, and 9 years. Conclusions: Anterior EAC reconstruction with autologous bone grafting can be an effective definitive treatment in TMJ herniation. To our knowledge, this is the first report of the use of bone grafting to reconstruct the canal defect in TMJ herniation. Level of Evidence: V.
- 28 July 2021
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 42 (10) , e1614-e1617
Reconstruction of the Anterior External Auditory Canal With Mastoid Cortex Autologous Bone Graft
Objective: To describe the surgical management of temporomandibular joint (TMJ) herniation with external auditory canal (EAC) reconstruction using autologous bone grafting from the mastoid cortex. Study Design: Retrospective case series. Setting: A tertiary university medical center. Patients: Three patients who presented to our Otolaryngology clinic with evidence of TMJ herniation through an anterior EAC defect, both on otoscopy and computed tomography (CT) imaging. Interventions: Reconstruction of the anterior EAC with mastoid cortex bone grafting using an endaural approach. Main Outcome Measures: Successful reconstruction of anterior EAC bony defect without recurrence of herniation. Results: All three patients presented with otalgia, hearing loss, and either tinnitus or a clicking sensation with jaw movement. Etiologies for TMJ herniation included osteoradionecrosis following external beam radiation therapy for head and neck carcinoma and iatrogenic injury following multiple tympanoplasties and canalplasties. A mastoid cortex bone graft was placed and secured anterior to the bony EAC defect through an endaural approach. Two patients wore a dental retainer postoperatively to keep the condyle in an open position. After reconstruction, patients reported an improvement in their presenting symptoms. There was no recurrence of TMJ herniation in all cases after 1, 4, and 9 years. Conclusions: Anterior EAC reconstruction with autologous bone grafting can be an effective definitive treatment in TMJ herniation. To our knowledge, this is the first report of the use of bone grafting to reconstruct the canal defect in TMJ herniation. Level of Evidence: V.
- 26 February 2013
- Published by Wiley in The Laryngoscope
- Vol. 123 (4) , 823-828
Sinonasal Disease in Polyostotic Fibrous Dysplasia and McCune–Albright Syndrome
Objectives/Hypothesis: To characterize the spectrum, symptoms, progression, and effects of endocrine dysfunction on sinonasal disease in polyostotic fibrous dysplasia (PFD) and McCune–Albright Syndrome (MAS). Study Design: Retrospective review. Methods: A prospectively followed cohort of subjects with PFD/MAS underwent a comprehensive evaluation that included otolaryngologic and endocrine evaluation, and imaging studies. Head and facial computed tomography scans were analyzed, and the degree of fibrous dysplasia (FD) was graded using a modified Lund–MacKay scale. Those followed for >4 years were analyzed for progression. Results: A total of 106 patients meeting inclusion criteria were identified with craniofacial FD. A majority (92%) demonstrated sinonasal involvement. There were significant positive correlations between the sinonasal FD scale score and chronic congestion, hyposmia, growth hormone excess, and hyperthyroidism (P < .05 for all). Significant correlations were not found for headache/facial pain or recurrent/chronic sinusitis. Thirty-one subjects met the criteria for longitudinal analysis (follow-up mean, 6.3 years; range, 4.4–9 years). Those who demonstrated disease progression were significantly younger than those who did not (mean age, 11 vs. 25 years). Progression after age of 13 years was uncommon (n = 3) and minimal. Concomitant endocrinopathy or bisphosphonate use did not have any significant effect on progression of disease. Conclusions: Sinonasal involvement of fibrous dysplasia in PFD/MAS is common. Symptoms are usually few and mild, and disease progression occurs primarily in young subjects. Concomitant endocrinopathy is associated with disease severity, but not progression.
- 26 February 2013
- Published by Wiley in The Laryngoscope
- Vol. 123 (4) , 823-828
Sinonasal Disease in Polyostotic Fibrous Dysplasia and McCune–Albright Syndrome
Objectives/Hypothesis: To characterize the spectrum, symptoms, progression, and effects of endocrine dysfunction on sinonasal disease in polyostotic fibrous dysplasia (PFD) and McCune–Albright Syndrome (MAS). Study Design: Retrospective review. Methods: A prospectively followed cohort of subjects with PFD/MAS underwent a comprehensive evaluation that included otolaryngologic and endocrine evaluation, and imaging studies. Head and facial computed tomography scans were analyzed, and the degree of fibrous dysplasia (FD) was graded using a modified Lund–MacKay scale. Those followed for >4 years were analyzed for progression. Results: A total of 106 patients meeting inclusion criteria were identified with craniofacial FD. A majority (92%) demonstrated sinonasal involvement. There were significant positive correlations between the sinonasal FD scale score and chronic congestion, hyposmia, growth hormone excess, and hyperthyroidism (P < .05 for all). Significant correlations were not found for headache/facial pain or recurrent/chronic sinusitis. Thirty-one subjects met the criteria for longitudinal analysis (follow-up mean, 6.3 years; range, 4.4–9 years). Those who demonstrated disease progression were significantly younger than those who did not (mean age, 11 vs. 25 years). Progression after age of 13 years was uncommon (n = 3) and minimal. Concomitant endocrinopathy or bisphosphonate use did not have any significant effect on progression of disease. Conclusions: Sinonasal involvement of fibrous dysplasia in PFD/MAS is common. Symptoms are usually few and mild, and disease progression occurs primarily in young subjects. Concomitant endocrinopathy is associated with disease severity, but not progression.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 121
Frameless Fractionated Stereotactic Radiosurgery for Vestibular Schwannomas: A Single-Institution Experience
Objective: To examine tumor control, hearing preservation, and complication rates after frameless fractionated stereotactic radiosurgery (SRS) in patients with vestibular schwannomas (VS). Methods: Thirty-seven patients treated with fractionated SRS from 2002 to 2011 were retrospectively analyzed. Ninety-five percent were treated with 25 Gy in five fractions, targeting a median tumor volume of 1.03 cc (range 0.14–7.60). Results: With a median follow-up of 4.25 years (range, 15 months–9 years), no tumors required an additional treatment resulting in 100% tumor control rate. Radiographic control rate was 91% in 32 patients at a median follow-up of 3 years. Of the 14 patients with serviceable hearing and with audiograms, the hearing preservation rate was 78% at a median follow-up of 18 months. Twenty-six patients with serviceable hearing pretreatment, were evaluated by a phone survey with a hearing preservation rate of 73% at a 5 year median follow-up. There were two cases that developed both new increased trigeminal parasthesias and facial spasms but there were no cases of facial weakness. Patient had 96% of good to excellent satisfaction rate with the treatment at a median follow-up of 5 years. Conclusion: Frameless fractionated SRS treatment of VS results in good rate of tumor control. Hearing preservation rate and rates of cranial nerve toxicity are comparable to what is reported in the literature. Patients choose this modality because of its non-invasive nature and are generally very satisfied with their long term outcome.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 121
Open AccessFrameless Fractionated Stereotactic Radiosurgery for Vestibular Schwannomas: A Single-Institution Experience
Objective: To examine tumor control, hearing preservation, and complication rates after frameless fractionated stereotactic radiosurgery (SRS) in patients with vestibular schwannomas (VS). Methods: Thirty-seven patients treated with fractionated SRS from 2002 to 2011 were retrospectively analyzed. Ninety-five percent were treated with 25 Gy in five fractions, targeting a median tumor volume of 1.03 cc (range 0.14–7.60). Results: With a median follow-up of 4.25 years (range, 15 months–9 years), no tumors required an additional treatment resulting in 100% tumor control rate. Radiographic control rate was 91% in 32 patients at a median follow-up of 3 years. Of the 14 patients with serviceable hearing and with audiograms, the hearing preservation rate was 78% at a median follow-up of 18 months. Twenty-six patients with serviceable hearing pretreatment, were evaluated by a phone survey with a hearing preservation rate of 73% at a 5 year median follow-up. There were two cases that developed both new increased trigeminal parasthesias and facial spasms but there were no cases of facial weakness. Patient had 96% of good to excellent satisfaction rate with the treatment at a median follow-up of 5 years. Conclusion: Frameless fractionated SRS treatment of VS results in good rate of tumor control. Hearing preservation rate and rates of cranial nerve toxicity are comparable to what is reported in the literature. Patients choose this modality because of its non-invasive nature and are generally very satisfied with their long term outcome.
- 17 May 2012
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 147 (4) , 744-749
Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma
Objective: To understand the audiologic and vestibular toxicities associated with adoptive cell immunotherapy (ACI) targeting pigment‐pathway antigens on melanoma and to investigate the use of intratympanic steroid injections in the treatment of these toxicities.Study Design: Prospective nonrandomized study.Setting: Tertiary clinical research center.Methods: Thirty‐two patients with progressive metastatic melanoma who failed conventional therapy underwent ACI with T cells genetically modified to target MART‐1 (n = 18) or gp100 (n = 14). All patients received serial audiometric testing. Vestibular testing was performed on patients with vestibular complaints. Patients with significant deficits received intratympanic steroid injections.Results: Of 32 patients, 15 had no hearing change, 9 had mild hearing loss, and 8 had moderate hearing loss following treatment. Ten patients received intratympanic steroid injections for mild (n = 2) or moderate (n = 7) hearing loss or for significant imbalance (n = 1). Of those with mild hearing loss (n = 9), all but 1 recovered to pretreatment hearing levels. Four of 8 patients with moderate hearing loss recovered to baseline hearing levels, and 4 had partial recovery. All 7 patients with posttreatment vestibular complaints had demonstrable vestibular dysfunction. Three of these patients demonstrated recovery to normal vestibular function. The number of modified T cells infused for therapy correlated with the degree of audiovestibular deficit.Conclusion: Adoptive cell immunotherapy targeting pigment‐pathway cell proteins, a novel therapy for melanoma, can induce hearing loss and vestibular dysfunction. The presumed mechanism of autoimmune attack on normal melanocytes in the cochlear stria vascularis and in the vestibular organs demonstrates the importance of melanocytes in normal inner ear function.
- 17 May 2012
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 147 (4) , 744-749
Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma
Objective: To understand the audiologic and vestibular toxicities associated with adoptive cell immunotherapy (ACI) targeting pigment‐pathway antigens on melanoma and to investigate the use of intratympanic steroid injections in the treatment of these toxicities.Study Design: Prospective nonrandomized study.Setting: Tertiary clinical research center.Methods: Thirty‐two patients with progressive metastatic melanoma who failed conventional therapy underwent ACI with T cells genetically modified to target MART‐1 (n = 18) or gp100 (n = 14). All patients received serial audiometric testing. Vestibular testing was performed on patients with vestibular complaints. Patients with significant deficits received intratympanic steroid injections.Results: Of 32 patients, 15 had no hearing change, 9 had mild hearing loss, and 8 had moderate hearing loss following treatment. Ten patients received intratympanic steroid injections for mild (n = 2) or moderate (n = 7) hearing loss or for significant imbalance (n = 1). Of those with mild hearing loss (n = 9), all but 1 recovered to pretreatment hearing levels. Four of 8 patients with moderate hearing loss recovered to baseline hearing levels, and 4 had partial recovery. All 7 patients with posttreatment vestibular complaints had demonstrable vestibular dysfunction. Three of these patients demonstrated recovery to normal vestibular function. The number of modified T cells infused for therapy correlated with the degree of audiovestibular deficit.Conclusion: Adoptive cell immunotherapy targeting pigment‐pathway cell proteins, a novel therapy for melanoma, can induce hearing loss and vestibular dysfunction. The presumed mechanism of autoimmune attack on normal melanocytes in the cochlear stria vascularis and in the vestibular organs demonstrates the importance of melanocytes in normal inner ear function.
- 31 March 2011
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 145 (2) , 295-302
Cryopyrin‐Associated Periodic Syndromes
Objective: Cryopyrin‐associated periodic syndromes (CAPS) represent a spectrum of CIAS1 gene‐mediated autoinflammatory diseases characterized by recurrent systemic inflammation. The clinical spectrum of CAPS varies from mild to severe and includes the syndromes historically described as familial cold autoinflammatory syndrome (FCAS), Muckle‐Wells syndrome (MWS), and neonatal‐onset multisystem inflammatory disease (NOMID). This article presents the largest cohort of patients with CAPS. The objective is to describe the pathogenesis, otolaryngologic, and audiologic manifestations of CAPS.Study Design: Prospective (2003‐2009).Setting: National Institutes of Health.Subjects and Methods: Fifty‐seven patients with a diagnosis of CAPS were identified (31 NOMID, 11 NOMID/MWS, 9 MWS, and 6 FCAS). Comprehensive data regarding clinical manifestations, audiologic phenotype, and fluid attenuation inversion recovery MRI (FLAIR‐MRI) of the brain and inner ear were obtained.Results: Complete audiologic data obtained on 70% of ears revealed conductive hearing loss in 4 (11%) NOMID ears and mixed hearing loss in 5 (13%) NOMID and 2 (14%) NOMID/MWS ears. Sensorineural hearing loss (SNHL), worse in higher frequencies, was the most common type of hearing loss and was present in 23 (61%) NOMID, 10 (71%) NOMID/MWS, and 4 (33%) MWS ears. All of the patients with FCAS had normal hearing except 2, who had SNHL from 4 to 8 kHz. On FLAIR‐MRI sequence, cochlear enhancement was noted in 26 of 29 (90%) NOMID, 6 of 11 (55%) NOMID/MWS, 3 of 9 (33%) MWS, and 1 of 6 (17%) FCAS patients and was significantly associated with the presence of hearing loss. Maxillary sinus hypoplasia and mucosal thickening were found in 39% and 86% of the cohort, respectively.Conclusion: CIAS1 pathway–mediated CAPS is associated with unregulated autoinflammation mediated by interleukin‐1 in the cochlea and hearing loss. Timely diagnosis is crucial to initiate early treatment with interleukin‐1 receptor antagonists.
- 31 March 2011
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 145 (2) , 295-302
Cryopyrin‐Associated Periodic Syndromes
Objective: Cryopyrin‐associated periodic syndromes (CAPS) represent a spectrum of CIAS1 gene‐mediated autoinflammatory diseases characterized by recurrent systemic inflammation. The clinical spectrum of CAPS varies from mild to severe and includes the syndromes historically described as familial cold autoinflammatory syndrome (FCAS), Muckle‐Wells syndrome (MWS), and neonatal‐onset multisystem inflammatory disease (NOMID). This article presents the largest cohort of patients with CAPS. The objective is to describe the pathogenesis, otolaryngologic, and audiologic manifestations of CAPS.Study Design: Prospective (2003‐2009).Setting: National Institutes of Health.Subjects and Methods: Fifty‐seven patients with a diagnosis of CAPS were identified (31 NOMID, 11 NOMID/MWS, 9 MWS, and 6 FCAS). Comprehensive data regarding clinical manifestations, audiologic phenotype, and fluid attenuation inversion recovery MRI (FLAIR‐MRI) of the brain and inner ear were obtained.Results: Complete audiologic data obtained on 70% of ears revealed conductive hearing loss in 4 (11%) NOMID ears and mixed hearing loss in 5 (13%) NOMID and 2 (14%) NOMID/MWS ears. Sensorineural hearing loss (SNHL), worse in higher frequencies, was the most common type of hearing loss and was present in 23 (61%) NOMID, 10 (71%) NOMID/MWS, and 4 (33%) MWS ears. All of the patients with FCAS had normal hearing except 2, who had SNHL from 4 to 8 kHz. On FLAIR‐MRI sequence, cochlear enhancement was noted in 26 of 29 (90%) NOMID, 6 of 11 (55%) NOMID/MWS, 3 of 9 (33%) MWS, and 1 of 6 (17%) FCAS patients and was significantly associated with the presence of hearing loss. Maxillary sinus hypoplasia and mucosal thickening were found in 39% and 86% of the cohort, respectively.Conclusion: CIAS1 pathway–mediated CAPS is associated with unregulated autoinflammation mediated by interleukin‐1 in the cochlea and hearing loss. Timely diagnosis is crucial to initiate early treatment with interleukin‐1 receptor antagonists.